A 4-year observation in lupus nephritis patients treated with an intensified B-lymphocyte depletion without immunosuppressive maintenance treatment-Clinical response compared to literature and immunological re-assessment

Autoimmunity Reviews

Volumn 14, Issue 12, 2015, Pages 1123-1130

  Roccatello, Dario ^a,b   Sciascia, Savino ^a   Baldovino, Simone ^a   Rossi, Daniela ^a   Alpa, Mirella ^a   Naretto, Carla ^a   Di Simone, Debora ^a   Simoncini, Matteo ^a   Menegatti, Elisa ^a  

^a Center of Piemonte and Valle d'Aosta Network for Rare Diseases   (Italy)

^b S GIOVANNI BOSCO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1; INTERLEUKIN 37; IMMUNOSUPPRESSIVE AGENT;

ANKYLOSING SPONDYLITIS; AUTOIMMUNE DISEASE; GRAVES DISEASE; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; INFLAMMATION; INFLAMMATORY BOWEL DISEASE; INNATE IMMUNITY; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; B LYMPHOCYTE; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; IMMUNOLOGY; LUPUS NEPHRITIS; LYMPHOCYTE DEPLETION; OBSERVATIONAL STUDY;

B-LYMPHOCYTES; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS; LYMPHOCYTE DEPLETION; OBSERVATIONAL STUDIES AS TOPIC;

EID: 84945457234     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2015.07.017     Document Type: Review

References (44)

1. Yaniv G., Twig G., Shor D.B., Furer A., Sherer Y., Mozes O., et al. A volcanic explosion of autoantibodies in systemic lupus erythematosus: a diversity of 180 different antibodies found in SLE patients. Autoimmun Rev 2015, 14(1):75-79.
2. Kamal A., Khamashta M. The efficacy of novel B cell biologics as the future of SLE treatment: a review. Autoimmun Rev 2014, 13(11):1094-1101.
3. Gregersen J.W., Jayne D.R. B-Cell depletion in the treatment of lupus nephritis. Nat Rev Nephrol 2012, 8(9):505-514.
4. Greco A., De Virgilio A., Rizzo M.I., Gallo A., Magliulo G., Fusconi M., et al. Microscopic polyangiitis: advances in diagnostic and therapeutic approaches. Autoimmun Rev 2015, 14(9):837-844.
5. Piatek C.I., El-Hemaidi I., Feinstein D.I., Liebman H.A., Akhtari M. Management of immune-mediated cytopenias in pregnancy. Autoimmun Rev 2015, 14:806-811.
6. Greco A., Rizzo M.I., De Virgilio A., Gallo A., Fusconi M., Ruoppolo G., et al. Churg-Strauss syndrome. Autoimmun Rev 2015, 14:341-348.
7. Ahmed A.R., Shetty S. A comprehensive analysis of treatment outcomes in patients with pemphigus vulgaris treated with rituximab. Autoimmun Rev 2015, 14:323-331.
8. Reynaud Q., Durieu I., Dutertre M., Ledochowski S., Durupt S., Michallet A.S., et al. Efficacy and safety of rituximab in auto-immune hemolytic anemia: a meta-analysis of 21 studies. Autoimmun Rev 2015, 14:304-313.
9. Moulis G., Lapeyre-Mestre M., Montastruc J.L., Sailler L. Exposure to non-corticosteroid treatments in adult primary immune thrombocytopenia before the chronic phase in the era of thrombopoietin receptor agonists in France. A nationwide population-based study. Autoimmun Rev 2015, 14:168-173.
10. Erkan D., Aguiar C.L., Andrade D., Cohen H., Cuadrado M.J., Danowski A., et al. 14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends. Autoimmun Rev 2014, 13:685-696.
11. Roccatello D., Sciascia S., Rossi D., Alpa M., Naretto C., Baldovino S., et al. Intensive short-term treatment with rituximab, cyclophosphamide and methylprednisolone pulses induces remission in severe cases of SLE with nephritis and avoids further immunosuppressive maintenance therapy. Nephrol Dial Transplant 2011, 26:3987-3992.
12. Leah E. Therapy: Rituximab for refractory SLE-patients reach lasting remission with short-term regimen. Nat Rev Rheumatol 2011, 7:312.
13. Bertsias G.K., Tektonidou M., Amoura Z., Aringer M., Bajema I., Berden J.H., et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 2012, 71:1771-1782.
14. Sfikakis P.P., Boletis J.N., Lionaki S., Vigklis V., Fragiadaki K.G., Iniotaki A., et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum 2005, 52:501-513.
15. Vigna-Perez M., Hernandez-Castro B., Paredes-Saharopulos O., Portales-Perez D., Baranda L., Abud-Mendoza C., et al. Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res Ther 2006, 8:R83.
16. Lindholm C., Borjesson-Asp K., Zendjanchi K., Sundqvist A.C., Tarkowski A., Bokarewa M. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus. J Rheumatol 2008, 35:826-833.
17. Melander C., Sallee M., Trolliet P., Candon S., Belenfant X., Daugas E., et al. Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome. Clin J Am Soc Nephrol 2009, 4:579-587.
18. Boletis J.N., Marinaki S., Skalioti C., Lionaki S.S., Iniotaki A., Sfikakis P.P. Rituximab and mycophenolate mofetil for relapsing proliferative lupus nephritis: a long-term prospective study. Nephrol Dial Transplant 2009, 24:2157-2160.
19. Li E.K., Tam L.S., Zhu T.Y., Li M., Kwok C.L., Li T.K., et al. Is combination rituximab with cyclophosphamide better than rituximab alone in the treatment of lupus nephritis?. Rheumatology 2009, 48:892-898.
20. Pepper R., Griffith M., Kirwan C., Levy J., Taube D., Pusey C., et al. Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids. Nephrol Dial Transplant 2009, 24:3717-3723.
21. Garcia-Carrasco M., Mendoza-Pinto C., Sandoval-Cruz M., Soto-Vega E., Beltran-Castillo A., Jimenez-Hernandez M., et al. Anti-CD20 therapy in patients with refractory systemic lupus erythematosus: a longitudinal analysis of 52 Hispanic patients. Lupus 2010, 19:213-219.
22. Ramos-Casals M., Garcia-Hernandez F.J., de Ramon E., Callejas J.L., Martinez-Berriotxoa A., Pallares L., et al. Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases. Clin Exp Rheumatol 2010, 28:468-476.
23. Catapano F., Chaudhry A.N., Jones R.B., Smith K.G., Jayne D.W. Long-term efficacy and safety of rituximab in refractory and relapsing systemic lupus erythematosus. Nephrol Dial Transplant 2010, 25:3586-3592.
24. Davies R.J., Sangle S.R., Jordan N.P., Aslam L., Lewis M.J., Wedgwood R., et al. Rituximab in the treatment of resistant lupus nephritis: therapy failure in rapidly progressive crescentic lupus nephritis. Lupus 2013, 22:574-582.
25. Condon M.B., Ashby D., Pepper R.J., Cook H.T., Levy J.B., Griffith M., et al. Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis 2013, 72:1280-1286.
26. Jonsdottir T., Zickert A., Sundelin B., Henriksson E.W., van Vollenhoven R.F., Gunnarsson I. Long-term follow-up in lupus nephritis patients treated with rituximab-clinical and histopathological response. Rheumatology 2013, 52:847-855.
27. Moroni G., Raffiotta F., Trezzi B., Giglio E., Mezzina N., Del Papa N., et al. Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: a clinical observational study. Rheumatology 2014, 53:1570-1577.
28. Rovin B.H., Furie R., Latinis K., Looney R.J., Fervenza F.C., Sanchez-Guerrero J., et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 2012, 64:1215-1226.
29. Roccatello D., Sciascia S., Rossi D., Alpa M., Naretto C., Russo A., et al. Long-term effects of rituximab added to cyclophosphamide in refractory patients with vasculitis. Am J Nephrol 2011, 34:175-180.
30. Roccatello D., Baldovino S., Alpa M., Rossi D., Napoli F., Naretto C., et al. Effects of anti-CD20 monoclonal antibody as a rescue treatment for ANCA-associated idiopathic systemic vasculitis with or without overt renal involvement. Clin Exp Rheumatol 2008, 26:S67-S71.
31. Cavallo R., Roccatello D., Menegatti E., Naretto C., Napoli F., Baldovino S. Rituximab in cryoglobulinemic peripheral neuropathy. J Neurol 2009, 256:1076-1082.
32. Roccatello D., Baldovino S., Rossi D., Mansouri M., Naretto C., Gennaro M., et al. Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis. Nephrol Dial Transplant 2004, 19:3054-3061.
33. Sciascia S., Naretto C., Rossi D., Bazzan M., Roccatello D. Treatment-induced downregulation of antiphospholipid antibodies: effect of rituximab alone on clinical and laboratory features of antiphospholipid syndrome. Lupus 2011, 20:1106-1108.
34. Ramos-Casals M., Brito-Zeron P., Munoz S., Soto M.J., Group B.S. A systematic review of the off-label use of biological therapies in systemic autoimmune diseases. Medicine 2008, 87:345-364.
35. Vital E.M., Dass S., Buch M.H., Henshaw K., Pease C.T., Martin M.F., et al. B cell biomarkers of rituximab responses in systemic lupus erythematosus. Arthritis Rheum 2011, 63:3038-3047.
36. Dumoitier N., Terrier B., London J., Lofek S., Mouthon L. Implication of B lymphocytes in the pathogenesis of ANCA-associated vasculitides. Autoimmun Rev 2015, 14:996-1004.
37. Visentini M., Tinelli C., Colantuono S., Monti M., Ludovisi S., Gragnani L., et al. Efficacy of low-dose rituximab for the treatment of mixed cryoglobulinemia vasculitis: Phase II clinical trial and systematic review. Autoimmun Rev 2015, 14:889-896.
38. Berman H., Rodriguez-Pinto I., Cervera R., Morel N., Costedoat-Chalumeau N., Erkan D., et al. Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab. Autoimmun Rev 2013, 12:1085-1090.
39. Anolik J.H., Campbell D., Felgar R.E., Young F., Sanz I., Rosenblatt J., et al. The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 2003, 48:455-459.
40. Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 2005, 6:345-352.
41. von Boehmer H. Mechanisms of suppression by suppressor T cells. Nat Immunol 2005, 6:338-344.
42. Sfikakis P.P., Souliotis V.L., Fragiadaki K.G., Moutsopoulos H.M., Boletis J.N., Theofilopoulos A.N. Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis. Clin Immunol 2007, 123:66-73.
43. Ramos-Casals M., Diaz-Lagares C., Khamashta M.A. Rituximab and lupus: good in real life, bad in controlled trials. Comment on the article by Lu et al. Arthritis Rheum 2009, 61:1281-1282.
44. Lu T.Y., Ng K.P., Cambridge G., Leandro M.J., Edwards J.C., Ehrenstein M., et al. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. Arthritis Rheum 2009, 61:482-487.